WOMEN'S HEALTH: TRENDS AND OPPORTUNITIES IN THE U.S. OSTEOPOROSIS MANAGEMENT MARKET

150 Pages | 37 Exhibits | 2013 Analysis | Forecasts Through 2017 Product Family: Market Reports




OVERVIEW:
In the United States (U.S.), the rate of osteoporosis is expected to grow significantly as the population ages. It is estimated that approximately 9 million adults in the U.S. have osteoporosis and more than 48 million have low bone mass, placing them at risk for developing osteoporosis. Assuming that prevalence of osteoporosis and low bone mass remains unchanged, by the year 2020, it is projected that 10.7 million adults in the U.S. will have osteoporosis and 58.2 million will have low bone mass.

This dynamic new report from Medtech Insight includes analyses of products, competitors, and opportunities in the U.S. market for osteoporosis diagnosis and treatment products. During the forecast period covered by this report, the U.S. market for osteoporosis management products is projected to grow to an estimated $6.4 billion by the year 2017. This market, as covered by the scope of this report, includes diagnostic products (including bone densitometry systems and bone remodeling biochemical marker tests) and current and emerging pharmaceutical treatments (including bisphosphonates, estrogen agonists/antagonists, estrogen and estrogen/progestin therapies, monoclonal antibody inhibitors, salmon calcitonin, and synthetic parathyroid hormone).

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Osteoporosis Incidence and Prevalence
ii. Osteoporosis Diagnosis and Management
	a. Bone Densitometry
	b. Biochemical Markers
	c. Pharmaceutical Treatments
iii. Market Analysis
	a. Bone Densitometry Systems
	b. Biochemical Markers
	c. Pharmaceutical Treatments
		i. Estrogen/Hormone Therapy Drugs
		ii. Osteoporosis Drugs
iv. Methodology

Exhibit ES-1: 2012, Osteoporosis-Caused Fracture Incidence, by Site
Exhibit ES-2: Osteoporosis Management Products, Combined Market Forecast, 2012-2017
Exhibit ES-3: Bone Densitometry Systems, Market Forecast, 2012-2017
Exhibit ES-4: Bone Remodeling Biochemical Marker Tests, Market Forecast, 2012-2017
Exhibit ES-5: Pharmaceutical Treatments for Osteoporosis, Market Forecast, 2012-2017
Exhibit ES-6: 2012, Pharmaceutical Treatments for Osteoporosis, Sales by Product Category

1. OVERVIEW OF OSTEOPOROSIS

1.1 Incidence, Prevalence, and Cost
1.2 Types of Osteoporosis
1.3 Risk Factors

Exhibit 1-1: Osteoporotic Bone and Normal Bone
Exhibit 1-2: 2012, Osteoporosis-Caused Fracture Incidence, by Site
Exhibit 1-3: Osteoporosis or Low Bone Mass in Women Age 50 and Older, by Race and Ethnicity
Exhibit 1-4: Types of Osteoporosis
Exhibit 1-5: Leading Risk Factors for Osteoporosis

2. BONE DENSITOMETRY PRODUCTS MARKET

2.1 Bone Densitometry Overview
	2.1.1 Dual-Energy X-Ray Absorptiometry
	2.1.2 Single-Energy X-Ray Absorptiometry
	2.1.3 Radiographic Absorptiometry
	2.1.4 Quantitative Computed Tomography
	2.1.5 Quantitative Ultrasound
	2.1.6 Hospital-Based Densitometry Systems
	2.1.7 Office-Based Densitometry Systems
	2.1.8 Software-Based Densitometry Systems
2.2 Densitometry Products
	2.2.1 BeamMed
	2.2.2 CompuMed
	2.2.3 CooperSurgical/The Cooper Companies
	2.2.4 Furuno USA/Furuno Electric Company
	2.2.5 GE Healthcare/General Electric Company
	2.2.6 Hologic
	2.2.7 Lone Oak Medical Technologies
	2.2.8 Sectra
2.3 Reimbursement
2.4 Market Analysis
2.5 Competitive Analysis

Exhibit 2-1: Comparison of Biochemical Markers and Bone Densitometry as Tools for Diagnosing and Monitoring Osteoporosis
Exhibit 2-2: Imaging Technologies Used to Diagnose Osteoporosis
Exhibit 2-3: 2013, Selected Bone Densitometry Systems
Exhibit 2-4: The Sunlight MiniOmni Bone Sonometer
Exhibit 2-5: The Norland Family of Dual-Energy X-Ray Absorptiometry Systems
Exhibit 2-6: The Lunar iDXA Dual-Energy X-Ray Absorptiometry System
Exhibit 2-7: The Discovery Dual-Energy X-Ray Absorptiometry System
Exhibit 2-8: The OsteoGram Radiographic Absorptiometry System
Exhibit 2-9: The CM-200 Quantitative Ultrasound Bone Densitometry System
Exhibit 2-10: The Accudxa2 Dual-Energy X-Ray Absorptiometry System
Exhibit 2-11: Hospital-Based Bone Densitometry Systems, Market Forecast, 2012-2017
Exhibit 2-12: Office-Based Bone Densitometry Systems, Market Forecast, 2012-2017
Exhibit 2-13: Total Bone Densitometry Systems, Market Forecast, 2012-2017
Exhibit 2-14: 2012, Bone Densitometry Systems Market, Share by Supplier

3. BONE REMODELING BIOCHEMICAL MARKER TESTS MARKET

3.1 Biochemical Markers Overview
	3.1.1 Types of Bone Turnover Markers
	3.1.2 Applications
3.2 Biochemical Marker Testing Products
	3.2.1 Alere
	3.2.2 Beckman Coulter
	3.2.3 Roche Diagnostics/Roche
	3.2.4 Immunodiagnostic Systems
	3.2.5 Orion Diagnostica/Orion Group
	3.2.6 Quidel
3.3 Reimbursement
3.4 Market Analysis
3.5 Competitive Analysis

Exhibit 3-1: The Bone Remodeling Cycle
Exhibit 3-2: Comparison of Selected Bone Remodeling Biochemical Marker Tests
Exhibit 3-3: 2013, Selected Bone Remodeling Biochemical Marker Tests
Exhibit 3-4: Bone Remodeling Biochemical Marker Tests, Market Forecast, 2012-2017
Exhibit 3-5: 2012, Bone Remodeling Biochemical Marker Tests Market, Share by Supplier

4. OSTEOPOROSIS PHARMACEUTICAL TREATMENTS MARKET

4.1 Clinical Overview
	4.1.1 Antiresorptive Drugs
		4.1.1.1 Bisphosphonates
			4.1.1.1.1 Alendronate
			4.1.1.1.2 Ibandronate
			4.1.1.1.3 Risedronate
			4.1.1.1.4 Zoledronate
		4.1.1.2 Salmon Calcitonins
			4.1.1.2.1 Novartis
			4.1.1.2.2 Unigene Laboratories
			4.1.1.2.3 Emerging Drugs
		4.1.1.3 Estrogen/Hormone Therapy
		4.1.1.4 Receptor Activator of Nuclear Factor KappaB Ligand Inhibitors
		4.1.1.5 Estrogen Agonists/Antagonists
			4.1.1.5.1 Emerging Drugs
				4.1.1.5.1.1 Pfizer
				4.1.1.5.1.2 EndoCeutics
		4.1.1.6 Other Emerging Antiresorptives
			4.1.1.6.1 Cathepsin K Inhibitors
			4.1.1.6.2 Monoclonal Antibodies
				4.1.1.6.2.1 Alethia Biotherapeutics
				4.1.1.6.2.2 Novo Nordisk
	4.1.2 Bone-Forming Drugs
		4.1.2.1 Synthetic Parathyroid Hormone
			4.1.2.1.1 Forteo
			4.1.2.1.2 Pipeline Drugs
				4.1.2.1.2.1 Radius Health
		4.1.2.2 Other Emerging Anabolic Drugs
			4.1.2.2.1 Serotonin Inhibitors
	4.1.3 Bone Morphogenetic Proteins
	4.1.4 Dual-Action Bone Agents
		4.1.4.1 Strontium Ranelate
		4.1.4.2 Strontium Malonate
	4.1.5 Gene Therapy
4.2 Market Analysis
	4.2.1 Estrogen/Hormone Therapy Drugs
	4.2.2 Osteoporosis Drugs
		4.2.2.1 Bone-Building Drugs
		4.2.2.2 Bisphosphonates
		4.2.2.3 Receptor Activator of Nuclear Factor KappaB Ligand Inhibitors
		4.2.2.4 Salmon Calcitonin
4.3 Competitive Analysis

Exhibit 4-1: 2013, Selected Pharmaceutical Treatments for Osteoporosis
Exhibit 4-2: 2013, Selected Emerging Pharmaceutical Treatments for Osteoporosis
Exhibit 4-3: Estrogen/Hormone Therapy and Osteoporosis Drugs, Market Forecast, 2012-2017
Exhibit 4-4: 2012, Estrogen/Hormone Therapy and Osteoporosis Drugs, Sales by Product Category
Exhibit 4-5: United States Patent Status of Selected Estrogen/ Hormone Therapy Drugs
Exhibit 4-6: United States Patent Status of Selected Osteoporosis Drugs
Exhibit 4-7: 2012, Estrogen/Hormone Therapy and Osteoporosis Drugs Market, Share by Supplier

5. COMPANY PROFILES

5.1 Alere, Inc
5.2 The Cooper Companies, Inc
5.3 GE Healthcare/General Electric Company
5.4 Hologic, Inc
5.5 Eli Lilly and Company
5.6 Novartis AG
5.7 Pfizer, Inc
5.8 Roche Holding AG

APPENDIX: COMPANY LISTING


COMPANIES COVERED:

  1. 3M Company
  2. Abbott Laboratories, Inc.
  3. Actavis, Inc.
  4. Alere, Inc.
  5. Alethia Biotherapeutics, Inc.
  6. Amgen, Inc.
  7. Apotex, Inc.
  8. Aurobindo Pharma LTD
  9. Bayer HealthCare Pharmaceuticals/Bayer HealthCare AG/Bayer AG
  10. BeamMed LTD
  11. Beckman Coulter, Inc.
  12. Carestream Health, Inc.
  13. CompuMed, Inc.
  14. CooperSurgical, Inc./The Cooper Companies, Inc.
  15. EffRx SA
  16. Emisphere Technologies, Inc.
  17. EndoCeutics, Inc.
  18. Fujifilm Medical Systems USA, Inc./Fujifilm Corporation
  19. Furuno Electric Company LTD
  20. GE Healthcare/General Electric Company
  21. Genentech, Inc./Roche Group
  22. GlaxoSmithKline PLC
  23. Hologic, Inc.
  24. Immunodiagnostic Systems Holdings PLC
  25. Ipsen Group
  26. Ligand Pharmaceuticals, Inc.
  27. Eli Lilly and Company
  28. Lone Oak Medical Technologies LLC
  29. Medtronic, Inc.
  30. Merck & Company, Inc.
  31. Mission Pharmacal Company
  32. Mylan, Inc.
  33. Nordic Bioscience A/S
  34. Novartis AG
  35. Noven Pharmaceuticals, Inc.
  36. Novogyne Pharmaceuticals/Novartis Pharmaceuticals Corporation and Noven Pharmaceuticals, Inc.
  37. Novo Nordisk, Inc./Novo Nordisk A/S
  38. NPS Pharmaceuticals, Inc.
  39. Orion Diagnostica Oy/Orion Corporation
  40. Osteologics Holdings PLC
  41. Par Pharmaceutical Companies, Inc.
  42. Pfizer, Inc.
  43. Procter & Gamble Company
  44. Quest Diagnostics, Inc.
  45. Quidel Corporation
  46. Radius Health, Inc.
  47. Roche Holding AG/Roche Group
  48. Sanofi SA
  49. Sectra AB
  50. Servier SA
  51. Siemens AG
  52. SkelRegen LLC
  53. Sun Pharma Global, Inc./Sun Pharmaceutical Industries LTD
  54. Swissray International, Inc.
  55. Syneron Medical LTD
  56. Tarsa Therapeutics, Inc.
  57. Teva Pharmaceutical Industries LTD
  58. UCB SA
  59. Upsher-Smith Laboratories, Inc.
  60. Warner Chilcott Company LLC
  61. Zosano Pharma, Inc.
Contact Us

Need help finding medtech research? Let us help you!